KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $24.9 billion.

  • Vertex Pharmaceuticals' Liabilities and Shareholders Equity rose 1178.99% to $24.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $94.3 billion, marking a year-over-year increase of 594.56%. This contributed to the annual value of $22.5 billion for FY2024, which is 86.67% down from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Liabilities and Shareholders Equity of $24.9 billion as of Q3 2025, which was up 1178.99% from $24.0 billion recorded in Q2 2025.
  • Vertex Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $24.9 billion during Q3 2025, with a 5-year trough of $12.1 billion in Q1 2021.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $20.1 billion (2024), whereas its average is $18.9 billion.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Liabilities and Shareholders Equity skyrocketed by 3622.83% in 2021 and then tumbled by 433.53% in 2025.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Liabilities and Shareholders Equity stood at $13.4 billion in 2021, then skyrocketed by 35.13% to $18.2 billion in 2022, then rose by 25.23% to $22.7 billion in 2023, then fell by 0.87% to $22.5 billion in 2024, then grew by 10.34% to $24.9 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $24.9 billion for Q3 2025, versus $24.0 billion for Q2 2025 and $22.9 billion for Q1 2025.